The question of whether serum calcitonin levels should be routinely measured in the initial work-up of with a patient with thyroid nodular disease remains unresolved. Indeed, calcitonin screening ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer. The study is published in the peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback